Inozyme Pharma Inc

NASDAQ:INZY   11:37:26 AM EDT
15.75
+0.31 (+2.01%)
Products, Regulatory

Inozyme Pharma Receives Orphan Drug Designation For Inz-701 From The European Medicines Agency For The Treatment Of Abcc6 Deficiency

Published: 07/21/2021 11:44 GMT
Inozyme Pharma Inc (INZY) - Inozyme Pharma Receives Orphan Drug Designation for Inz-701 From the European Medicines Agency for the Treatment of Abcc6 Deficiency.
Inozyme - Preparing to Initiate a Phase 1/2 Clinical Trial in Patients With Enpp1 Deficiency in Mid 2021.
Inozyme Pharma Inc - Preparing to Initiate a Separate Phase 1/2 Clinical Trial in Patients With Abcc6 Deficiency in Mid-2021.